[ad_1]
METAVAX is a platform for the development of vaccines based on enveloped virus-like particle nanostructures (eVLPs) based on the small surface antigen of duck hepatitis B. SplitCore is the technology in which capsid virus-like particles (cVLP) are applied as antigen-presenting vehicles without the involvement of host lipid membrane structures.
The ARTES development approach is designed to present domains of the SARS-CoV-2 spike protein, with or without an antigen derived from the virus nucleocapsid protein, on the surface of eVLP (METAVAX) and cVLP (SplitCore).
The virus-like particles mimic the conformation of true native viruses without being infectious. They consist of one or more structural proteins that have the ability to self-assemble to mimic the structure of real viruses and present foreign epitopes or complete antigens on their surface. Due to the lack of a viral genome, recombinant VLPs are superior to native viruses and at the same time maintain the same potential to trigger a strong immune response.
In September 2019, ARTES and the Burnett Institute of Australia published data on the efficient production of candidate malaria vaccines using virus-like particles (eVLPs) produced with the ARTES METAVAX platform that present antigens at the stage of malaria transmission. , which were able to induce antibodies that block transmission.
